Johnson & Johnson told the US Food and Drug Administration on July 22. The drug's phase 4 monotherapy data showed that symptoms of depression improved rapidly within 24 hours and continued for at least 4 weeks. Spravato is currently approved for use in combination with oral antidepressants to treat depressive symptoms in adult TRD patients and adults with severe depression with acute suicidal ideation or behavior.

Johnson & Johnson told the US Food and Drug Administration on July 22. The drug's phase 4 monotherapy data showed that symptoms of depression improved rapidly within 24 hours and continued for at least 4 weeks. Spravato is currently approved for use in combination with oral antidepressants to treat depressive symptoms in adult TRD patients and adults with severe depression with acute suicidal ideation or behavior.